Introduction
von Willebrand disease (VWD) is the most common inherited bleeding disorder with a prevalence estimated to range from 1 to 100 in 10 000 [1] . VWD is caused by quantitative (Types 1 and 3) or qualitative (Type 2) deficiency in von Willebrand factor (VWF) and is markedly heterogeneous in type and severity [1] [2] [3] [4] . Surgical procedures in patients with VWD can be associated with a life-threatening risk of excessive bleeding and may require prophylactic treatment with a combined VWF/FVIII concentrate [5] . Dosing of VWF/FVIII concentrates for surgical haemostasis depends on disease severity and surgery type [6] . Several prospective and retrospective studies have demonstrated the haemostatic effect of VWF/FVIII-containing concentrates in surgical procedures [5, [7] [8] [9] [10] [11] [12] [13] [14] . Although rare, repeated administrations of VWF/FVIII products, as often needed during surgery, have been associated with thrombotic events linked to abnormally high plasma levels of FVIII coagulant activity (FVIII:C) or VWF ristocetin cofactor activity (VWF:RCo) [15] .
Wilate ® is a double virus-inactivated, plasmaderived concentrate with the native VWF and FVIII complex in a physiological 1:1 activity ratio [7, [16] [17] [18] . The efficacy, safety and tolerability of wilate ® in the prevention and treatment of bleeding in adults and children with VWD have been reported in several prospective clinical trials [7, 8, [19] [20] [21] , which included surgical procedures. This current study (WONDERS) investigated the clinical efficacy and safety of wilate ® in the prevention and treatment of surgical bleeding, under well-defined, stringent protocol-driven and centrally monitored conditions, in patients with inherited VWD.
Methods

Study design
A prospective, open-label, multinational, phase III clinical study was performed in paediatric and adult patients with inherited VWD undergoing surgery to evaluate the haemostatic efficacy and safety of wilate ® in maintaining intra-and postoperative haemostasis in surgical procedures (ClinicalTrials.gov Identifier: NCT01365546). The study originally planned to examine up to 41 surgical procedures. A single interim analysis was planned after 30 procedures, with the possibility for early study termination if predefined success criteria were achieved. Early success was defined by a two-sided 98.75% confidence interval (CI) for the overall success rate of >0.60 (equivalent to ≥25 successes in 30 procedures). The interim analysis showed that the prespecified success rate for study termination was reached after 30 procedures. Patients could have multiple independent surgeries that were counted as separate surgical events. Patients were monitored for 30 days from the start of each surgery or until discharge, whichever came later. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice guidelines, and national regulatory requirements [22] . The final protocol was reviewed and approved by the responsible regulatory authorities and institutional ethics committees.
Enrolment criteria
The study enrolled males or females aged ≥6 years with inherited VWD (any type) requiring a VWF/FVIII concentrate to cover surgical procedures. Patients were excluded if they had any other known coagulation disorder, had received a VWF/FVIII-containing product within 3 days of the screening visit, had any known inhibitor activity against VWF or FVIII and if continuous infusion was planned. Additional exclusion criteria included: active hepatic disease, known or suspected hypersensitivity and receiving immune-modulating drugs at study start. Patients or parents/legal guardians of paediatric patients provided full informed consent.
Dosing
All doses were administered as a bolus intravenous infusion. All patients received 60 IU kg À1 of wilate ® for the in vivo recovery (IVR) investigation at study start to calculate the recommended dosing for surgeries; additionally, the following guidelines were given:
Major surgery. A loading dose of 40-60 VWF:RCo IU kg À1 within 3 h of start of procedure was given to achieve peak plasma VWF:RCo level of 100%. A maintenance dose of 20-40 VWF:RCo IU kg À1 or half of the loading dose was given every 12-24 h. Trough levels of VWF:RCo were to be maintained at >50% for at least 6 days. At least two maintenance doses were to be administered within the first 24 h after the start of surgery.
Minor surgery. A loading dose of 30-60 VWF:RCo IU kg À1 within 3 h of start of procedure was given to achieve peak plasma VWF: RCo level of 50%. A maintenance dose of 20-40 VWF: RCo IU kg À1 or half of the loading dose was given every 12-24 h. Trough levels of VWF: RCo were to be maintained at >30% for at least 2 days.
These dosing recommendations were adjusted for each patient using the results of the baseline IVR and at the investigator's discretion based on the clinical situation. FVIII:C and VWF:RCo levels were monitored throughout the treatment period, with the aim of not exceeding a recommended maximum level of 250% FVIII:C and maintaining a recommended trough level of at least 50% VWF:RCo for major surgeries and 30% VWF:RCo for minor surgeries. No VWF/FVIII preparations other than wilate ® were to be administered, except in emergency situations.
Efficacy and safety evaluations
Surgical prophylaxis. Efficacy of wilate ® was assessed by the surgeon at the end of each surgical procedure (last suture) using a stringent and objective 4-point efficacy scale (excellent, good, moderate or none) based on blood loss and transfusion requirements during surgery, and postoperatively by the investigator based on postoperative bleeding and oozing, covering the time period from the end of the procedure up to 24 h following the last wilate ® infusion. In the event of a discrepancy between surgeons' and investigators' assessments, falling into one of the categories marked 'primary adjudication' in Table 1 , the classification of success or failure was determined by the Independent Data Monitoring Committee (IDMC).
Plasma levels of haemostatic parameters and IVR. IVR of FVIII:C, VWF:RCo and von Willebrand factor antigen (VWF:Ag) were determined at a central laboratory for all patients at the screening/baseline visit, and used to calculate the recommended dosing (VWF:RCo). Plasma levels of haemostatic parameters and IVR were additionally determined for every maintenance infusion 30 min before and after every infusion. These plasma samples were analysed locally for monitoring purposes and confirmed later by the central laboratory.
Safety. Clinical tolerability was assessed by monitoring vital signs, laboratory parameters (including VWF inhibitors and virus markers) and adverse events.
Statistics
The primary analysis focused on the overall proportion of surgeries rated as successful (Table 1) . For the overall efficacy assessment, a CI of 98.75% was used, and for the intra-and postoperative assessment, a CI of 95% was used.
Results
Patient demographics
The study enrolled 39 individual patients (safety population), of whom 28 individual patients underwent 30 surgeries (intent-to-treat [ITT] population). All 39 enrolled patients were included in the safety population as all received an infusion of wilate ® for IVR determination, but not all underwent surgery. As the prespecified criteria for success were met at the interim analysis, the study was terminated early (after 30 surgeries). Demographic characteristics (ITT) are shown in Table 2 . Median (range) baseline levels of VWF:RCo were 22.5 IU dL 
Efficacy in surgical prophylaxis
Of the 30 surgical procedures, 21 were major and nine were minor. Of the 21 procedures in VWD Type 3 patients, 17 (81.0%) were major. Major procedures included orthopaedic (8) , obstetric/gynaecological (5), gastrointestinal (4), dental (2) and ear, nose and throat (2) surgeries. Minor procedures included dental (5), orthopaedic (2), ophthalmologic (1) and ear, nose and throat (1) surgeries.
The overall success rate of wilate ® treatment was 96.7% based on objective criteria and as adjudicated by the IDMC (98.75% CI: 0.784, 1.000) (Table 3A) . In the event of a discrepancy between surgeons' and investigators' assessments, falling into one of the categories marked 'primary adjudication', the classification of success or failure was determined by the IDMC. In addition, the IDMC conducted an independent and blinded adjudication of all haemostatic efficacy results ('secondary adjudication'), and the overall success (primary endpoint) was based on both the intra-and postoperative IDMC efficacy assessments. ) underwent left lumbar spine laminectomy (major surgery). The blood loss observed was slightly greater (25 mL) than the expected maximum in a patient with normal haemostasis (20 mL). No transfusions or additional doses of VWF/FVIII concentrate were needed for this patient. Postoperatively, the patient developed bruising and induration, and the wound had healed by the time the patient was discharged. The investigator later noted that these issues were due to an intraoperative complication.
Dosing for surgical procedures
Exposure to wilate ® during surgeries and the dosages required are summarized in Table 4 (Table 1) , only the lumbar laminectomy was classified as a treatment failure in cases of higher than expected blood loss. Intraoperative transfusions were electively planned for five patients undergoing major surgeries, but were only required in two patients. In these patients, the mean actual transfusion volume (287.5 mL) was lower than Table 3 . Haemostatic efficacy assessment by severity of surgery (A) and type of VWD (B). the mean expected volume (1190 mL). Aminocaproic acid and tranexamic acid were planned and administered intraoperatively in five patients.
Plasma levels of haemostatic parameters over time FVIII:C, VWF:RCo and VWF:Ag plasma levels were monitored throughout the postoperative period. Figure 2 shows mean peak and trough levels over time in all surgeries (Fig. 2a) , major surgeries (Fig. 2b ) and minor surgeries (Fig. 2c) . Mean plasma levels of haemostatic parameters remained stable during maintenance dose administrations. While VWF:RCo trough levels were sometimes low between maintenance doses, FVIII levels were sufficient to maintain haemostasis. Six patients had instances of FVIII:C values >250 IU dL À1 (range: 256-395) during maintenance infusions; however, in most cases, this correlated with higher dosing, which was corrected by decreasing the dose. No accumulation of FVIII:C was observed over time and no thromboembolic events occurred. Three patients received two loading doses and one patient received three loading doses. These additional loading doses were not administered due to insufficient efficacy of the initial dose, but due to delays in the start of surgery or to a presurgical procedure. 
Recovery investigations over time
The majority of IVR values for FVIII and VWF were in the expected range over the entire study period (Fig. 3) . Several patients had IVR values that were higher or lower than physiologically plausible, but nearly all of these outliers were present at only one or two time points, and could be attributed to possible errors in the assay or sample handling.
Safety and tolerability
The mean cumulative dose per procedure for the 30 surgical procedures (in 28 patients) was 24 653 IU (739 590 IU overall). Of 262 exposure days to wilate ® , 250 were for surgical prophylaxis. The duration of wilate ® treatment following major and minor surgery is shown in Fig. 4 .
Eight non-serious adverse events in five patients were considered to be probably related to treatment, and included hypersensitivity, chest discomfort, feeling hot, dizziness and decrease in blood pressure. All were mild or moderate in intensity, and all resolved without sequelae. One of these patients experienced moderate hypersensitivity that led to discontinuation of wilate ® during the presurgery loading infusion. The patient subsequently withdrew consent and received no further wilate ® infusions. The investigator/nurse noted that the patient appeared extremely anxious and timeconscious and that the symptoms were most likely related to anxiety. Postoperative haematomas occurred in four procedures (three patients); however, none required evacuation.
There were no thromboembolic events and antithrombotic agents were not administered to any patients. No VWF or FVIII inhibitors or virus seroconversions were observed.
Discussion
This prospective study addressed the efficacy and safety of wilate ® in the maintenance of haemostasis in patients with inherited VWD undergoing surgery. The study used stringent, objective efficacy criteria to assess efficacy during and after surgical procedures, as well as blinded adjudication of all efficacy assessments by the IDMC and statistical analysis, to provide a conservative, unbiased efficacy assessment of wilate ® . The use of objective assessment criteria for surgical prophylaxis in this study is in line with recently developed objective efficacy criteria in non-surgical settings [23] .
The success of wilate ® in surgical prophylaxis was established at the planned interim analysis in all but one (29/30) surgical procedures. As the prespecified success criteria were met, the study was terminated early as recommended by the IDMC. The overall success rate was 96.7% (98.75% CI: 0.784, 1.000). This is particularly noteworthy in the light of the high percentage of major surgeries performed (70%) and that Number of patients
Post-surgery day
Minor surgeries Major surgeries 70% were in VWD Type 3. All procedures in Type 3 patients were successful. In addition, although the number of paediatric procedures was low (three surgeries in three patients), efficacy was rated as excellent or good in all procedures. The overall haemostatic efficacy rate obtained in this study is in line with a previous pooled analysis of four prospective clinical trials that included evaluation of wilate ® efficacy during surgery [7] . In the pooled analysis (53 rated procedures in 32 patients), efficacy was excellent or good in 51 of 53 (96%) procedures. Also consistent with the results from this study are those reported in VWD patients receiving wilate ® in real-life, clinical settings in the UK [8, 24] . Based on a subjective 4-point scale, surgical efficacy of wilate ® in the UK cohort was rated excellent or good in 66 of 70 (94%) procedures (34 patients). Therefore, despite the objective, more stringent efficacy criteria used in this study, efficacy rates were similar to those reported in studies using more subjective criteria.
A number of studies evaluating the efficacy of VWF/ FVIII concentrates other than wilate ® in a surgical setting have been published. In two prospective studies, Humate-P ® was deemed effective (excellent or good overall efficacy) in 94.3% and 100% of 35 elective surgeries and 42 urgent surgical procedures, respectively [13, 14] . The overall number of patients with VWD Type 3 was much lower in these studies compared with this study (37% and 21% vs. 70%), although the proportion of major procedures was comparable (71% and 60% vs. 70%). In a review of several VWF/FVIII concentrates other than wilate ® , efficacy rates during surgery ranged from 91% to 100%, as assessed by mostly subjective criteria [10] .
In this study, wilate ® dosing was comparable or lower than dosing reported for other concentrates in VWD patients undergoing surgery. In this study, patients received a median loading dose per infusion of 52. , respectively [12, 13] . Although rare, thromboembolic complications are a concern in surgeries covered with any VWF/FVIII concentrate due to the potentially frequent and high doses administered over a longer period and possible accumulation of VWF and FVIII. Plasma levels of VWF and FVIII remained stable during wilate ® maintenance dose administrations and no sustained FVIII accumulation over time or thromboembolic events were observed during this study. In contrast, accumulation of FVIII has been observed in studies with other VWF/FVIII concentrates [12, 14] . In one study with Humate-P ® , a modest rise in FVIII:C was observed over time in some patients, with nine patients experiencing FVIII:C >200 IU dL À1 in 52 instances [14] . In another study with Haemate ® P, FVIII:C progressively increased before each therapeutic/maintenance dose, suggesting some accumulation of FVIII over time [12] . Additionally, one patient developed a pulmonary embolism during the study, with a high FVIII:C plasma level of 450 IU dL À1 recorded the previous day. The data in this study indicate that a product with a 1:1 VWF to FVIII ratio can be easily dosed using a FVIII haemostatic target. In addition, dosing can be based on either VWF:RCo or FVIII:C IU as observed plasma levels run in parallel after repeat dosing. The parallel decay curves for VWF and FVIII activity was predicted from the single-dose pharmacokinetics of wilate ® , which was shown to be significantly different from other VWF concentrates [17] . FVIII accumulation is not seen in these data, which should reduce the issue of increased thrombogenicity with multiple dosing that has been reported with other VWF/FVIII concentrates. Moreover, using a FVIII assay to predict VWF levels enables more convenient monitoring. Given that peak FVIII:C plasma levels were mostly between 125 and 150% and trough levels between 75 and 100% during major surgeries, it is likely that haemostasis could be achieved with 25-30% lower doses of wilate ® if FVIII:C was used as a marker for adequacy of haemostasis instead of targeting presumed haemostatic levels of VWF:RCo. Such an approach would avoid reaching unnecessarily high levels of FVIII:C, which are implicated in increased thrombotic risk, and in most cases would be easier to perform and be potentially more reliable.
No treatment-related severe or serious adverse events occurred in this study. Importantly, no cases of VWF or FVIII inhibitors were observed and no virus seroconversions occurred. We therefore conclude that wilate ® is well tolerated and effective in achieving surgical haemostasis in patients with all types of VWD with no accumulation of FVIII after repeat dosing.
